Search alternatives:
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
10 mg » 100 mg (Expand Search), 50 mg (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
10 mg » 100 mg (Expand Search), 50 mg (Expand Search)
-
121
-
122
-
123
-
124
-
125
-
126
Rhinorrhea-free days up to day 10.
Published 2024“…Patients were randomized in a 1:1:1 ratio to receive halofuginone 0.5mg, 1mg or placebo orally once daily for 10 days. …”
-
127
Vomit-free days up to day 10.
Published 2024“…Patients were randomized in a 1:1:1 ratio to receive halofuginone 0.5mg, 1mg or placebo orally once daily for 10 days. …”
-
128
Symptoms free-days up to day 10.
Published 2024“…Patients were randomized in a 1:1:1 ratio to receive halofuginone 0.5mg, 1mg or placebo orally once daily for 10 days. …”
-
129
Diarrhea-free days up to day 10.
Published 2024“…Patients were randomized in a 1:1:1 ratio to receive halofuginone 0.5mg, 1mg or placebo orally once daily for 10 days. …”
-
130
Nausea-free days up to day 10.
Published 2024“…Patients were randomized in a 1:1:1 ratio to receive halofuginone 0.5mg, 1mg or placebo orally once daily for 10 days. …”
-
131
Cough-free days up to day 10.
Published 2024“…Patients were randomized in a 1:1:1 ratio to receive halofuginone 0.5mg, 1mg or placebo orally once daily for 10 days. …”
-
132
Dyspnea-free days up to day 10.
Published 2024“…Patients were randomized in a 1:1:1 ratio to receive halofuginone 0.5mg, 1mg or placebo orally once daily for 10 days. …”
-
133
<i>Trans ε</i> viniferin decreases amyloid deposits and inflammation in a mouse transgenic Alzheimer model
Published 2019“…Here, effects of this stilbenoid were evaluated in transgenic APPswePS1dE9 mice. We report that <i>trans ε</i>-viniferin could go through the blood brain barrier, reduces size and density of amyloid deposits and decreases reactivity of astrocytes and microglia, after a weekly intraperitoneal injection at 10 mg/kg from 3 to 6 months of age.…”
-
134
-
135
-
136
-
137
-
138
-
139
-
140